Pelthos Therapeutics Inc (PTHS) reports a 129% increase in prescriptions and strategic acquisitions, bolstering its financial ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Pelthos Therapeutics Inc. (PTHS) delivered earnings and revenue surprises of +28.35% and +3.78%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the ...

Pelthos Therapeutics Inc. (NYSE:PTHS) on Thursday announced the launch of Zelsuvmi (berdazimer) topical gel 10.3% for molluscum contagiosum (molluscum) in adults and pediatric patients one year of age ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Uncrowned is a new destination for all things MMA, boxing, wrestling, and more, featuring Ariel Helwani. Yahoo Racing is powered by Motorsport Network, providing expert reporting, analysis, and ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Good morning, everyone, and welcome to Pelthos Therapeutics 2025 Fourth Quarter and Fiscal Year Financial Results Conference Call. Pelthos issued a press release today announcing its financial results ...

Pelthos Therapeutics Inc. (PTHS) stock price is 23.12 and Pelthos Therapeutics Inc. (PTHS) 10-day simple moving average is 23.69. Pelthos Therapeutics Inc. (PTHS) stock price is 23.12 and Pelthos ...